<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VALPROATE SODIUM- valproate sodium injection </strong><br>West-Ward Pharmaceutical Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use valproate sodium injection safely and effectively. See full prescribing information for valproate sodium injection.<br><br></span><span class="Bold">Valproate Sodium Injection, USP for intravenous injection<br></span><span class="Bold">Initial U.S. Approval: 1996<br><br>NOVAPLUS<span class="Sup">®</span><br><br></span>
</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold"><span class="Bold">WARNING: LIFE THREATENING ADVERSE REACTIONS<br></span></span><span class="Italics"><span class="Bold">See full prescribing information for complete boxed warning</span></span>
</h1>
<ul class="Disk">
<li><span class="Bold">Hepatotoxicity, including fatalities, usually during first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. Monitor patients closely, and perform serum liver function tests prior to therapy and at frequent intervals thereafter (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span></li>
<li><span class="Bold">Fetal Risk, particularly <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, other major malformations, and decreased IQ (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>, <a href="#LINK_57047296-0423-46d6-b660-a5feaf241ca2">5.4</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, including fatal hemorrhagic cases (<a href="#LINK_88f2fc36-7a47-48db-b98b-fd688ae57f0e">5.5</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>)                                                                                   1/2015  </p>
<p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and Other Hematopeietic Disorders (<a href="#LINK_cb12e87c-0574-46c5-b0a5-c603a0e2f452">5.7</a>)                                1/2015  </p>
<p class="Highlighta">Warnings and Precautions, Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span> (<a href="#LINK_0712022e-aec0-4130-825e-80aa14a5ed16">5.11</a>)                                 1/2015 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold"><span class="Bold">WARNING: LIFE THREATENING ADVERSE REACTIONS<br></span></span><span class="Italics"><span class="Bold">See full prescribing information for complete boxed warning</span></span>
</h1>
<ul class="Disk">
<li><span class="Bold">Hepatotoxicity, including fatalities, usually during first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. Monitor patients closely, and perform serum liver function tests prior to therapy and at frequent intervals thereafter (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span></li>
<li><span class="Bold">Fetal Risk, particularly <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, other major malformations, and decreased IQ (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>, <a href="#LINK_57047296-0423-46d6-b660-a5feaf241ca2">5.4</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, including fatal hemorrhagic cases (<a href="#LINK_88f2fc36-7a47-48db-b98b-fd688ae57f0e">5.5</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Valproate Sodium Injection, USP is an anti-epileptic drug and is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions: </p>
<ul class="Disk"><li>Monotherapy and adjunctive therapy of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> and simple and complex absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; adjunctive therapy in patients with multiple <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types that include absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<a href="#LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">1</a>)</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Valproate sodium injection is intended for intravenous use only. </p>
<ul class="Disk"><li><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> 
<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span> in Adults and Children 10 years of age or older: Initial dose is 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. Maximum recommended dose is 60 mg/kg/day. (<a href="#LINK_e2c38d11-a12a-4b54-996e-edfd76bc071c">2.1</a>) 
</li>
<li>Simple and Complex Absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Initial dose is 10 to 15 mg/‌kg/‌day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. Maximum recommended dose is 60 mg/kg/day. (<a href="#LINK_e2c38d11-a12a-4b54-996e-edfd76bc071c">2.1</a>)</li>
</ul>
</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injection: 100 mg per mL in a 5 mL single dose vial (<a href="#LINK_453db056-8e5b-4a49-b3b1-e8b4f8ebef3d">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic disease</span> or significant hepatic dysfunction (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>, <a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>) </li>
<li>Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>, <a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</li>
<li>Suspected POLG-related disorder in children under two years of age (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>, <a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>, <a href="#LINK_0712022e-aec0-4130-825e-80aa14a5ed16">5.11</a>) </li>
<li>Urea cycle disorders (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>, <a href="#LINK_b8348d88-fd71-49bf-aa6f-3c2ff711ae47">5.6</a>) </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Hepatotoxicity; evaluate high risk populations and monitor serum liver tests (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> and decreased IQ following <span class="Italics">in utero </span>exposure; only use to treat pregnant women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> if other medications are unacceptable; should not be administered to a woman of childbearing potential unless essential (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>, <a href="#LINK_57047296-0423-46d6-b660-a5feaf241ca2">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>; valproate sodium injection should ordinarily be discontinued (<a href="#LINK_88f2fc36-7a47-48db-b98b-fd688ae57f0e">5.5</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and other hematopoietic disorders; monitor platelet counts and coagulation tests (<a href="#LINK_cb12e87c-0574-46c5-b0a5-c603a0e2f452">5.7</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span>; measure <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level if unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or changes in mental status (<a href="#LINK_b8348d88-fd71-49bf-aa6f-3c2ff711ae47">5.6</a>, <a href="#LINK_6b74d06c-f3ca-4651-85ec-07115d023be5">5.8</a>, <a href="#LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb">5.9</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span>; <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> has been reported during valproate therapy with or without associated <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>. This adverse reaction can also occur in patients using concomitant topiramate (<a href="#LINK_a590675a-3b5c-4092-a7a9-5fe7ab4e3878">5.10</a>) </li>
<li>Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>; discontinue valproate sodium injection (<a href="#LINK_0712022e-aec0-4130-825e-80aa14a5ed16">5.11</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> in the elderly can occur. Valproate sodium injection dosage should be increased slowly and with regular monitoring for fluid and nutritional intake (<a href="#LINK_e520f86e-c406-42ba-9e77-7f6badf42d01">5.13</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions occurring in at least 5% of patients treated with divalproex sodium in Monotherapy or Adjunctive <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span> Trials:  </p>
<ul class="Disk"><li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>/<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (<a href="#LINK_132160f1-1e33-429e-80f2-14aaa19415e8">6.1</a>) </li></ul>
<p class="Highlighta">Additional Adverse Reactions not included above that occurred in &gt; 0.5% of patients treated with valproate sodium injection:  </p>
<ul class="Disk"><li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">injection site inflammation</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, vasodilation (<a href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</a>) </li></ul>
<p class="Highlighta">Additional adverse reactions not included above that occurred in other clinical trials with divalproex sodium:  </p>
<ul class="Disk"><li><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (<a href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</a>) </li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-233-2001 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li>Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. Therefore increased monitoring of valproate and concomitant drug concentrations and dosage adjustment are indicated whenever enzyme-inducing or inhibiting drugs are introduced or withdrawn (<a href="#LINK_663e7a2b-d6ee-460f-901e-d48070b140dc">7.1</a>)</li>
<li>Aspirin, carbapenem antibiotics: Monitoring of valproate concentrations is recommended (<a href="#LINK_663e7a2b-d6ee-460f-901e-d48070b140dc">7.1</a>) 
</li>
<li>Co-administration of valproate can affect the pharmacokinetics of other drugs (e.g. diazepam, ethosuximide, lamotrigine, phenytoin) by inhibiting their metabolism or protein binding displacement (<a href="#LINK_63208369-dd09-4e71-add1-71ddc53bb919">7.2</a>) 
</li>
<li>Dosage adjustment of amitryptyline/nortryptyline, warfarin, and zidovudine may be necessary if used concomitantly with valproate sodium injection (<a href="#LINK_63208369-dd09-4e71-add1-71ddc53bb919">7.2</a>) 
</li>
<li>Topiramate: <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (<a href="#LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb">5.9</a>, <a href="#LINK_5bc6d43e-ad54-4c6e-ac45-fdb8790eec2d">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>Pregnancy: Valproate sodium injection can cause congenital malformations including <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> and decreased IQ. (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>, <a href="#LINK_3d64c32b-83e1-4932-925c-bf3fae007911">8.1</a>) 
</li>
<li>Pediatric: Children under the age of two years are at considerably higher risk of fatal hepatotoxicity (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>, <a href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</a>) 
</li>
<li>Geriatric: Reduce starting dose, increase dosage more slowly; monitor fluid and nutritional intake, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (<a href="#LINK_e520f86e-c406-42ba-9e77-7f6badf42d01">5.13</a>, <a href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: LIFE THREATENING ADVERSE REACTIONS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Important Limitations</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 General Dosing Advice</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hepatotoxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Decreased IQ Following <span class="Italics">in utero </span>Exposure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use in Women of
Childbearing Potential</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Urea Cycle Disorders</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and
Other Hematopoietic Disorders</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> associated with Concomitant Topiramate Use</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multi-organ
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Interaction with Carbapenem Antibiotics</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> in the Elderly</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Post-traumatic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Monitoring: Drug Plasma Concentration</a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Effect on Ketone and <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid Function Tests</span></a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Effect on HIV and CMV Viruses Replication</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-6.2" class="toc">6.2 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h2><a href="#section-6.3" class="toc">6.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Postmarketing
Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effects of Co-Administered Drugs on Valproate Clearance</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effects of Valproate on Other Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Topiramate</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_a8e87156-1790-4479-b994-930898fd7c9e"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: LIFE THREATENING ADVERSE REACTIONS</span></h1>
<p class="First"><span class="Bold">Hepatotoxicity </span></p>
<p><span class="Bold"><span class="Italics">General Population: </span></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, a loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months [see WARNINGS and PRECAUTIONS (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)].</span></p>
<p><span class="Bold">Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>, those with severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders accompanied by <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, and those with organic brain disease. When valproate sodium injection is used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups. </span></p>
<p><span class="Bold"><span class="Italics">Patients with Mitochondrial Disease: </span></span><span class="Bold">There is an increased risk of valproate-induced <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> and resultant <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase </span><span class="Bold">γ</span><span class="Bold"> (POLG) gene (e.g. Alpers Huttenlocher Syndrome). Valproate is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder [see CONTRAINDICATIONS (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)].</span></p>
<p><span class="Bold">In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, valproate should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with valproate for the development of acute <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice [see WARNINGS AND PRECAUTIONS (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)].</span></p>
<p><span class="Bold">Fetal Risk </span></p>
<p><span class="Bold">Valproate can cause major congenital malformations, particularly <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> (e.g., <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span>). In addition, valproate can cause decreased IQ scores following <span class="Italics">in utero </span>exposure.</span></p>
<p><span class="Bold">Valproate should only be used to treat pregnant women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> if other medications have failed to control their symptoms or are otherwise unacceptable.</span></p>
<p><span class="Bold">Valproate should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition. This is especially important when valproate use is considered for a condition not usually associated with permanent injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (e.g., <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>). Women should use effective contraception while using valproate [see WARNINGS AND PRECAUTIONS (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>, <a href="#LINK_57047296-0423-46d6-b660-a5feaf241ca2">5.4</a>) </span><span class="Bold">and</span><span class="Bold"> PATIENT COUNSELING INFORMATION (<a href="#LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd">17</a>)</span><span class="Bold">]. </span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> </span></p>
<p><span class="Bold">Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> can be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> that require prompt medical evaluation. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated [see WARNINGS AND PRECAUTIONS (<a href="#LINK_88f2fc36-7a47-48db-b98b-fd688ae57f0e">5.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_89e216a7-8b92-49d4-ada0-96ac04abc313"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a50b212a-9243-4106-bc4a-4da0dfb590e6"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">Valproate Sodium Injection, USP is indicated as an intravenous alternative in patients for whom oral administration of valproate products is temporarily not feasible in the following conditions: </p>
<p>Valproate Sodium Injection, USP is indicated as monotherapy and adjunctive therapy in the treatment of patients with <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> that occur either in isolation or in association with other types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Valproate Sodium Injection, USP is also indicated for use as sole and adjunctive therapy in the treatment of patients with simple and complex absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and adjunctively in patients with multiple <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types that include absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. </p>
<p>Simple absence is defined as very brief clouding of the sensorium or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. </p>
<p>See <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span> for statement regarding fatal hepatic dysfunction. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_61b79936-bd01-4170-9ff5-044981b9abaa"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Important Limitations</h2>
<p class="First">Because of the risk to the fetus of decreased IQ, <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition [see <span class="Bold">WARNINGS AND PRECAUTIONS </span><span class="Bold">(<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>, <a href="#LINK_57047296-0423-46d6-b660-a5feaf241ca2">5.4</a>)</span>, <span class="Bold">USE IN SPECIFIC POPULATIONS (<a href="#LINK_3d64c32b-83e1-4932-925c-bf3fae007911">8.1</a>)</span>, and <span class="Bold">PATIENT COUNSELING INFORMATION (<a href="#LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd">17</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_85590813-5e0e-4242-a548-b5a0b528e548"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e2c38d11-a12a-4b54-996e-edfd76bc071c"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">Valproate sodium injection is for intravenous use only.</p>
<p>Use of valproate sodium injection for periods of more than 14 days has not been studied. Patients should be switched to oral valproate products as soon as it is clinically feasible.</p>
<p>Valproate sodium injection should be administered as a 60 minute infusion (but not more than 20 mg/‌min) with the same frequency as the oral products, although plasma concentration monitoring and dosage adjustments may be necessary.</p>
<p>In one clinical safety study, approximately 90 patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and with no measurable plasma levels of valproate were given single infusions of valproate sodium injection (up to 15 mg/‌kg and mean dose of 1184 mg) over 5-10 minutes (1.5-3.0 mg/kg/min). Patients generally tolerated the more rapid infusions well [see <span class="Bold">ADVERSE REACTIONS (<a href="#LINK_132160f1-1e33-429e-80f2-14aaa19415e8">6.1</a>)</span>]. This study was not designed to assess the effectiveness of these regimens. For pharmacokinetics with rapid infusions, see <span class="Bold">CLINICAL PHARMACOLOGY (<a href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</a>)</span>.</p>
<p><span class="Bold">Initial Exposure to Valproate<br></span>The following dosage recommendations were obtained from studies utilizing oral divalproex sodium products.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span><br></span>For adults and children 10 years of age or older.</p>
<p><span class="Underline">Monotherapy (Initial Therapy)<br></span>Valproate sodium injection has not been systematically studied as initial therapy. Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.</p>
<p>The probability of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> increases significantly at total trough valproate plasma concentrations above 110 mcg/mL in females and 135 mcg/mL in males. The benefit of improved <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control with higher doses should be weighed against the possibility of a greater incidence of adverse reactions. </p>
<p><span class="Underline">Conversion to Monotherapy<br></span>Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50-100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. Concomitant antiepilepsy drug (AED) dosage can ordinarily be reduced by approximately 25% every 2 weeks. This reduction may be started at initiation of valproate sodium injection therapy, or delayed by 1 to 2 weeks if there is a concern that <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are likely to occur with a reduction. The speed and duration of withdrawal of the concomitant AED can be highly variable, and patients should be monitored closely during this period for increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency. </p>
<p><span class="Underline">Adjunctive Therapy<br></span>Valproate sodium injection may be added to the patient’s regimen at a dosage of 10 to 15 mg/‌kg/‌day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. If the total daily dose exceeds 250 mg, it should be given in divided doses.</p>
<p>In a study of adjunctive therapy for <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> in which patients were receiving either carbamazepine or phenytoin in addition to valproate, no adjustment of carbamazepine or phenytoin dosage was needed [see <span class="Bold">CLINICAL STUDIES (<a href="#LINK_4ef60d23-9b54-4faa-a092-111267f448ff">14</a>)</span>]. However, since valproate may interact with these or other concurrently administered AEDs as well as other drugs, periodic plasma concentration determinations of concomitant AEDs are recommended during the early course of therapy [see <span class="Bold">DRUG INTERACTIONS (<a href="#LINK_17266c45-cb57-428f-9e0a-08815b20594d">7</a>)</span>].</p>
<p><span class="Bold">Simple and Complex Absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span><br></span>The recommended initial dose is 15 mg/kg/day, increasing at one week intervals by 5 to 10 mg/‌kg/‌day until <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are controlled or side effects preclude further increases. The maximum recommended dosage is 60 mg/kg/day. If the total daily dose exceeds 250 mg, it should be given in divided doses.</p>
<p>A good correlation has not been established between daily dose, serum concentrations, and therapeutic effect. However, therapeutic valproate serum concentration for most patients with absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is considered to range from 50 to 100 mcg/mL. Some patients may be controlled with lower or higher serum concentrations [see <span class="Bold">CLINICAL PHARMACOLOGY (<a href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</a>)</span>].</p>
<p>As the valproate sodium injection dosage is titrated upward, blood concentrations of phenobarbital and/‌or phenytoin may be affected [see <span class="Bold">DRUG INTERACTIONS (<a href="#LINK_63208369-dd09-4e71-add1-71ddc53bb919">7.2</a>)</span>].</p>
<p>Antiepilepsy drugs should not be abruptly discontinued in patients in whom the drug is administered to prevent major <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> because of the strong possibility of precipitating <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> with attendant <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and threat to life.</p>
<p><span class="Underline">Replacement Therapy<br></span>When switching from oral valproate products, the total daily dose of valproate sodium injection should be equivalent to the total daily dose of the oral valproate product [see <span class="Bold">CLINICAL PHARMACOLOGY (<a href="#LINK_b2e74910-6622-4ed1-8296-a59406ca0f2a">12</a>)</span>], and should be administered as a 60 minute infusion (but not more than 20 mg/min) with the same frequency as the oral products, although plasma concentration monitoring and dosage adjustments may be necessary. Patients receiving doses near the maximum recommended daily dose of 60 mg/kg/day, particularly those not receiving enzyme-inducing drugs, should be monitored more closely. If the total daily dose exceeds 250 mg, it should be given in a divided regimen. There is no experience with more rapid infusions in patients receiving valproate sodium injection as replacement therapy. However, the equivalence shown between valproate sodium injection and oral valproate products (divalproex sodium) at steady state was only evaluated in an every 6 hour regimen. Whether, when valproate sodium injection is given less frequently (i.e., twice or three times a day), trough levels <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below those that result from an oral dosage form given via the same regimen, is unknown. For this reason, when valproate sodium injection is given twice or three times a day, close monitoring of trough plasma levels may be needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3572552b-3ca0-4674-be7e-53d8dd0ccb44"></a><a name="section-2.2"></a><p></p>
<h2>2.2 General Dosing Advice</h2>
<p class="First"><span class="Underline">Dosing in Elderly Patients<br></span>Due to a decrease in unbound clearance of valproate and possibly a greater sensitivity to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> in the elderly, the starting dose should be reduced in these patients. Dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. The ultimate therapeutic dose should be achieved on the basis of both tolerability and clinical response [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_e520f86e-c406-42ba-9e77-7f6badf42d01">5.13</a>)</span>, <span class="Bold">USE IN SPECIFIC POPULATIONS (<a href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</a>)</span> and <span class="Bold">CLINICAL PHARMACOLOGY (<a href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</a>)</span>].</p>
<p><span class="Underline">Dose-Related Adverse Reactions<br></span>The frequency of adverse effects (particularly elevated liver enzymes and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) may be dose-related. The probability of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> appears to increase significantly at total valproate concentrations of ≥ 110 mcg/mL (females) or ≥ 135 mcg/mL (males) [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_cb12e87c-0574-46c5-b0a5-c603a0e2f452">5.7</a>)</span>]. The benefit of improved therapeutic effect with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.</p>
<p><span class="Underline">Administration<br></span>Rapid infusion of valproate sodium injection has been associated with an increase in adverse reactions. There is limited experience with infusion times of less than 60 minutes or rates of infusion &gt; 20 mg/min in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> [see <span class="Bold">ADVERSE REACTIONS (<a href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</a>)</span>].</p>
<p>Valproate sodium injection should be administered intravenously as a 60 minute infusion, as noted above. It should be diluted with at least 50 mL of a compatible diluent. Any unused portion of the vial contents should be discarded.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
<p><span class="Underline">Compatibility and Stability<br></span>Valproate sodium injection was found to be physically compatible and chemically stable in the following parenteral solutions for at least 24 hours when stored in glass or polyvinyl chloride (PVC) bags at controlled room temperature 15º to 30°C (59º to 86°F).</p>
<ul class="Disk">
<li>dextrose (5%) injection, USP 
</li>
<li>sodium chloride (0.9%) injection, USP 
</li>
<li>lactated ringer’s injection, USP </li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_453db056-8e5b-4a49-b3b1-e8b4f8ebef3d"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Valproate Sodium Injection, USP, equivalent to 100 mg of valproic acid per mL, is a clear, colorless solution in 5 mL single dose vials, available in trays of 10 vials. </p>
<p>Recommended storage: Store vials at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. </p>
<p>No preservatives have been added. Unused portion of container should be discarded. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul class="Disk">
<li>Valproate sodium injection should not be administered to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or significant hepatic dysfunction [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span>]. </li>
<li>Valproate sodium injection is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see <span class="Bold">WARNINGS AND PRECAUTIONS </span><span class="Bold">(<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span>].</li>
<li>Valproate sodium injection is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_0712022e-aec0-4130-825e-80aa14a5ed16">5.11</a>)</span>]. </li>
<li>Valproate sodium injection is contraindicated in patients with known urea cycle disorders [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_b8348d88-fd71-49bf-aa6f-3c2ff711ae47">5.6</a>)</span>]. </li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hepatotoxicity</h2>
<p class="First"><span class="Italics">General Information on Hepatotoxicity</span></p>
<p><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> resulting in fatalities has occurred in patients receiving valproate. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, a loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months of valproate therapy. However, physicians should not rely totally on serum biochemistry since these tests may not be abnormal in all instances, but should also consider the results of careful interim medical history and physical examination. </p>
<p>Caution should be observed when administering valproate products to patients with a prior history of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients on multiple anticonvulsants, children, those with congenital <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>, those with severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders accompanied by <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, and those with organic brain disease may be at particular risk. See below, “Patients with Known or Suspected Mitochondrial Disease.?</p>
<p>Experience has indicated that children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those with the aforementioned conditions. When valproate sodium injection is used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. Use of valproate sodium injection has not been studied in children below the age of 2 years. </p>
<p>In progressively older patient groups experience in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> has indicated that the incidence of fatal hepatotoxicity decreases considerably. </p>
<p><span class="Italics">Patients with Known or Suspected Mitochondrial Disease</span></p>
<p>Valproate is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder [see <span class="Bold">CONTRAINDICATIONS </span>(<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)]. Valproate-induced <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> and liver-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported in patients with hereditary neurometabolic syndromes caused by mutations in the gene for mitochondrial DNA polymerase γ (POLG) (e.g., Alpers- Huttenlocher Syndrome) at a higher rate than those without these syndromes. Most of the reported cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> in patients with these syndromes have been identified in children and adolescents.</p>
<p>POLG-related disorders should be suspected in patients with a family history or suggestive symptoms of a POLG-related disorder, including but not limited to unexplained <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, refractory <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (focal, myoclonic), <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> at presentation, <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span>, psychomotor regression, axonal sensorimotor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="product-label-link" type="condition" conceptid="435242" conceptname="Cerebellar ataxia">cerebellar ataxia</span>, opthalmoplegia, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">complicated migraine</span> with occipital <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>. POLG mutation testing should be performed in accordance with current clinical practice for the diagnostic evaluation of such disorders. The A467T and W748S mutations are present in approximately 2/3 of patients with autosomal recessive POLG-related disorders.</p>
<p>In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, valproate should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with valproate for the development of acute <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with regular clinical assessments and serum liver test monitoring.</p>
<p>The drug should be discontinued immediately in the presence of significant hepatic dysfunction, suspected or apparent. In some cases, hepatic dysfunction has progressed in spite of discontinuation of drug [see <span class="Bold"><a href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">BOXED WARNING</a></span> and <span class="Bold">CONTRAINDICATIONS (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8ce9430d-57d5-45b3-863a-3a62957de503"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span></h2>
<p class="First">Valproate can cause fetal harm when administered to a pregnant woman. Pregnancy registry data show that maternal valproate use can cause <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> and other structural abnormalities (e.g., craniofacial defects, cardiovascular malformations, <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>, <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb malformations</span>). The rate of congenital malformations among babies born to mothers using valproate is about four times higher than the rate among babies born to epileptic mothers using other anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> monotherapies. Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> in the general population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Decreased IQ Following <span class="Italics">in utero </span>Exposure</h2>
<p class="First">Valproate can cause decreased IQ scores following <span class="Italics">in utero </span>exposure. Published epidemiological studies have indicated that children exposed to valproate <span class="Italics">in utero</span> have lower cognitive test scores than children exposed <span class="Italics">in utero </span>to either another antiepileptic drug or to no antiepileptic drugs. The largest of these studies<span class="Sup">1</span> is a prospective cohort study conducted in the United States and United Kingdom that found that children with prenatal exposure to valproate (n = 62) had lower IQ scores at age 6 (97 [95% C.I. 94-101]) than children with prenatal exposure to the other antiepileptic drug monotherapy treatments evaluated: lamotrigine (108 [95% C.I. 105–110]), carbamazepine (105 [95% C.I. 102–108]), and phenytoin (108 [95% C.I. 104–112]). It is not known when during pregnancy cognitive effects in valproate-exposed children occur. Because the women in this study were exposed to antiepileptic drugs throughout pregnancy, whether the risk for decreased IQ was related to a particular time period during pregnancy could not be assessed. </p>
<p>Although all of the available studies have methodological limitations, the weight of the evidence supports the conclusion that valproate exposure <span class="Italics">in utero</span> can cause decreased IQ in children. </p>
<p>In animal studies, offspring with prenatal exposure to valproate had malformations similar to those seen in humans and demonstrated neurobehavioral deficits [see <span class="Bold">USE IN SPECIFIC POPULATIONS (<a href="#LINK_3d64c32b-83e1-4932-925c-bf3fae007911">8.1</a>)</span>]. </p>
<p>Women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> who are pregnant or who plan to become pregnant should not be treated with valproate unless other treatments have failed to provide adequate symptom control or are otherwise unacceptable. In such women, the benefits of treatment with valproate during pregnancy may still outweigh the risks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_57047296-0423-46d6-b660-a5feaf241ca2"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use in Women of
Childbearing Potential</h2>
<p class="First">Because of the risk to the fetus of decreased IQ and major congenital malformations (including <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>), which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition. This is especially important when valproate use is considered for a condition not usually associated with permanent injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (e.g., <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>). Women should use effective contraception while using valproate. Women who are planning a pregnancy should be counseled regarding the relative risks and benefits of valproate use during pregnancy, and alternative therapeutic options should be considered for these patients [see <span class="Bold"><a href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">BOXED WARNING</a></span> and <span class="Bold">USE IN SPECIFIC POPULATIONS (<a href="#LINK_3d64c32b-83e1-4932-925c-bf3fae007911">8.1</a>)</span>].</p>
<p>To prevent major <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, valproate should not be discontinued abruptly, as this can precipitate <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> with resulting maternal and fetal <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and threat to life. </p>
<p>Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> in the general population. It is not known whether the risk of <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> or decreased IQ in the offspring of women receiving valproate is reduced by folic acid supplementation. Dietary folic acid supplementation both prior to conception and during pregnancy should be routinely recommended for patients using valproate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_88f2fc36-7a47-48db-b98b-fd688ae57f0e"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with rapid progression from initial symptoms to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some cases have occurred shortly after initial use as well as after several years of use. The rate based upon the reported cases exceeds that expected in the general population and there have been cases in which <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> recurred after rechallenge with valproate. In clinical trials, there were 2 cases of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> without alternative etiology in 2416 patients, representing 1044 patient-years experience. Patients and guardians should be warned that <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> can be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> that require prompt medical evaluation. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated [see <span class="Bold"><a href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">BOXED WARNING</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b8348d88-fd71-49bf-aa6f-3c2ff711ae47"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Urea Cycle Disorders</h2>
<p class="First">Valproate sodium is contraindicated in patients with known urea cycle disorders (UCD).</p>
<p><span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">Hyperammonemic encephalopathy</span>, sometimes fatal, has been reported following initiation of valproate therapy in patients with urea cycle disorders, a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase deficiency. Prior to the initiation of valproate therapy, evaluation for UCD should be considered in the following patients: 1) those with a history of unexplained <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> associated with a protein load, pregnancy-related or postpartum <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, unexplained <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, or history of elevated plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> or glutamine; 2) those with cyclical <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, episodic extreme <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, low BUN, or protein avoidance; 3) those with a family history of UCD or a family history of unexplained infant <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (particularly males); 4) those with other signs or symptoms of UCD. Patients who develop symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> while receiving valproate therapy should receive prompt treatment (including discontinuation of valproate therapy) and be evaluated for underlying urea cycle disorders [see <span class="Bold">CONTRAINDICATIONS (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)</span> and <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb">5.9</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cb12e87c-0574-46c5-b0a5-c603a0e2f452"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and
Other Hematopoietic Disorders</h2>
<p class="First">Valproate is associated with dose-related <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. In a clinical trial of valproate as monotherapy in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, 34/126 patients (27%) receiving approximately 50 mg/kg/day on average, had at least one value of platelets ≤ 75 x 10<span class="Sup">9</span>/L. Approximately half of these patients had treatment discontinued, with return of platelet counts to normal. In the remaining patients, platelet counts normalized with continued treatment. In this study, the probability of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> appeared to increase significantly at total valproate concentrations of ≥ 110 mcg/mL (females) or ≥ 135 mcg/mL (males). The therapeutic benefit which may accompany the higher doses should therefore be weighed against the possibility of a greater incidence of adverse effects. Valproate use has also been associated with decreases in other cell lines and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplasia</span>.</p>
<p>Because of reports of <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, inhibition of the secondary phase of platelet aggregation, and abnormal coagulation parameters (e.g., low fibrinogen, coagulation factor deficiencies, acquired von Willebrand’s disease), measurements of complete blood counts and coagulation tests are recommended before initiating therapy and at periodic intervals. It is recommended that patients receiving valproate sodium injection be monitored for blood counts and coagulation parameters prior to planned surgery and during pregnancy <span class="Italics">[see Use in Specific Populations (<a href="#LINK_3d64c32b-83e1-4932-925c-bf3fae007911">8.1</a>)]</span>. Evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, or a disorder of hemostasis/coagulation is an indication for reduction of the dosage or withdrawal of therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6b74d06c-f3ca-4651-85ec-07115d023be5"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> has been reported in association with valproate therapy and may be present despite normal liver function tests. In patients who develop unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or changes in mental status, <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> should be considered and an <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level should be measured. <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> should also be considered in patients who present with <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_a590675a-3b5c-4092-a7a9-5fe7ab4e3878">5.10</a>)</span>]. If <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> is increased, valproate therapy should be discontinued. Appropriate interventions for treatment of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> should be initiated, and such patients should undergo investigation for underlying urea cycle disorders [see <span class="Bold">CONTRAINDICATIONS (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)</span> and <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_b8348d88-fd71-49bf-aa6f-3c2ff711ae47">5.6</a>, <a href="#LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb">5.9</a>)</span>].</p>
<p>Asymptomatic elevations of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> are more common and when present, require close monitoring of plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels. If the elevation persists, discontinuation of valproate therapy should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> associated with Concomitant Topiramate Use</h2>
<p class="First">Concomitant administration of topiramate and valproate has been associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in patients who have tolerated either drug alone. Clinical symptoms of <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> often include acute alterations in level of consciousness and/or cognitive function with <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> can also be a manifestation of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_a590675a-3b5c-4092-a7a9-5fe7ab4e3878">5.10</a>)</span>]. In most cases, symptoms and signs abated with discontinuation of either drug. This adverse reaction is not due to a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>. It is not known if topiramate monotherapy is associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>. Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may be at an increased risk for <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. Although not studied, an interaction of topiramate and valproate may exacerbate existing defects or unmask deficiencies in susceptible persons. In patients who develop unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or changes in mental status, <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> should be considered and an <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level should be measured [see <span class="Bold">CONTRAINDICATIONS (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)</span> and <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_6b74d06c-f3ca-4651-85ec-07115d023be5">5.8</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a590675a-3b5c-4092-a7a9-5fe7ab4e3878"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span>, defined as an unintentional drop in body core temperature to &lt; 35°C (95°F), has been reported in association with valproate therapy both in conjunction with and in the absence of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>. This adverse reaction can also occur in patients using concomitant topiramate with valproate after starting topiramate treatment or after increasing the daily dose of topiramate [see <span class="Bold">DRUG INTERACTIONS (<a href="#LINK_5bc6d43e-ad54-4c6e-ac45-fdb8790eec2d">7.3</a>)</span>]. Consideration should be given to stopping valproate in patients who develop <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, which may be manifested by a variety of clinical abnormalities including <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and significant alterations in other major organ systems such as the cardiovascular and respiratory systems. Clinical management and assessment should include examination of blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0712022e-aec0-4130-825e-80aa14a5ed16"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multi-organ
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS), also known as Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, has been reported in patients taking valproate. DRESS may be fatal or life-threatening. DRESS typically, although not exclusively, presents with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and/or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, in association with other organ system involvement, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, hematological abnormalities, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, or <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> sometimes resembling an acute <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, may be present even though <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Valproate should be discontinued and not be resumed if an alternative etiology for the signs or symptoms cannot be established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d0417f60-3a88-4b97-88be-95dee3062c3c"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Interaction with Carbapenem Antibiotics</h2>
<p class="First">Carbapenem antibiotics (for example, ertapenem, imipenem, meropenem; this is not a complete list) may reduce serum valproate concentrations to subtherapeutic levels, resulting in loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control. Serum valproate concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproate concentrations drop significantly or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control deteriorates [see <span class="Bold">DRUG INTERACTIONS (<a href="#LINK_663e7a2b-d6ee-460f-901e-d48070b140dc">7.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e520f86e-c406-42ba-9e77-7f6badf42d01"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> in the Elderly</h2>
<p class="First">In a double-blind, multicenter trial of valproate in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (mean age = 83 years), doses were increased by 125 mg/day to a target dose of 20 mg/kg/day. A significantly higher proportion of valproate patients had <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> compared to placebo, and although not statistically significant, there was a higher proportion of patients with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Discontinuations for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> were also significantly higher than with placebo. In some patients with <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (approximately one-half), there was associated reduced nutritional intake and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. There was a trend for the patients who experienced these events to have a lower baseline albumin concentration, lower valproate clearance, and a higher BUN. In elderly patients, dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> [see <span class="Bold">DOSAGE AND ADMINISTRATION (<a href="#LINK_3572552b-3ca0-4674-be7e-53d8dd0ccb44">2.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a242bc9-8cf6-4535-9858-6cef6b5c48a6"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Post-traumatic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">A study was conducted to evaluate the effect of IV valproate in the prevention of post-traumatic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients with acute head injuries. Patients were randomly assigned to receive either IV valproate given for one week (followed by oral valproate products for either one or six months per random treatment assignment) or IV phenytoin given for one week (followed by placebo). In this study, the incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was found to be higher in the two groups assigned to valproate treatment compared to the rate in those assigned to the IV phenytoin treatment group (13% vs 8.5%, respectively). Many of these patients were critically ill with multiple and/or severe injuries, and evaluation of the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> did not suggest any specific drug-related causation. Further, in the absence of a concurrent placebo control during the initial week of intravenous therapy, it is impossible to determine if the mortality rate in the patients treated with valproate was greater or less than that expected in a similar group not treated with valproate, or whether the rate seen in the IV phenytoin treated patients was lower than would be expected. Nonetheless, until further information is available, it seems prudent not to use valproate sodium injection in patients with acute head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> for the prophylaxis of post-traumatic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f43e419d-0c99-47a2-9c4b-7fba068be4bb"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Monitoring: Drug Plasma Concentration</h2>
<p class="First">Since valproate may interact with concurrently administered drugs which are capable of enzyme induction, periodic plasma concentration determinations of valproate and concomitant drugs are recommended during the early course of therapy [see <span class="Bold">DRUG INTERACTIONS (<a href="#LINK_17266c45-cb57-428f-9e0a-08815b20594d">7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5a79a5e5-07e7-45d3-9b99-72ee17cf11e2"></a><a name="section-5.16"></a><p></p>
<h2>5.16 Effect on Ketone and <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid Function Tests</span></h2>
<p class="First">Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test.</p>
<p>There have been reports of altered <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> associated with valproate. The clinical significance of these is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2e45d6e2-f512-486d-a1e6-92a8985e4f93"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Effect on HIV and CMV Viruses Replication</h2>
<p class="First">There are <span class="Italics">in vitro</span> studies that suggest valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions. The clinical consequence, if any, is not known. Additionally, the relevance of these <span class="Italics">in vitro</span> findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. Nevertheless, these data should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described below and elsewhere in the labeling:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> [see <span class="Bold">Warnings and Precautions (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> [see <span class="Bold">Warnings and Precautions (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>)</span>]</li>
<li>Decreased IQ following <span class="Italics">in utero </span>exposure [see <span class="Bold">Warnings and Precautions (<a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> [see <span class="Bold">Warnings and Precautions (<a href="#LINK_88f2fc36-7a47-48db-b98b-fd688ae57f0e">5.5</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">Hyperammonemic encephalopathy</span> [see <span class="Bold">Warnings and Precautions (<a href="#LINK_b8348d88-fd71-49bf-aa6f-3c2ff711ae47">5.6</a>, <a href="#LINK_6b74d06c-f3ca-4651-85ec-07115d023be5">5.8</a>, <a href="#LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb">5.9</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and other hematopoietic disorders [see <span class="Bold">Warnings and Precautions (<a href="#LINK_cb12e87c-0574-46c5-b0a5-c603a0e2f452">5.7</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> [see <span class="Bold">Warnings and Precautions (<a href="#LINK_a590675a-3b5c-4092-a7a9-5fe7ab4e3878">5.10</a>)</span>]</li>
<li>Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> [see <span class="Bold">Warnings and Precautions (<a href="#LINK_0712022e-aec0-4130-825e-80aa14a5ed16">5.11</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> in the elderly [see <span class="Bold">Warnings and Precautions (<a href="#LINK_e520f86e-c406-42ba-9e77-7f6badf42d01">5.13</a>)</span>]</li>
</ul>
<p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>The adverse reactions that can result from valproate sodium injection use include all of those associated with oral forms of valproate. The following describes experience specifically with valproate sodium injection. Valproate sodium injection has been generally well tolerated in clinical trials involving 111 healthy adult male volunteers and 352 patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, given at doses of 125 to 6,000 mg (total daily dose). A total of 2% of patients discontinued treatment with valproate sodium injection due to adverse reactions. The most common adverse reactions leading to discontinuation were 2 cases each of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and elevated amylase. Other adverse reactions leading to discontinuation were <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, and <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span> were observed more frequently at a 100 mg/‌min infusion rate than at rates up to 33 mg/min. At a 200 mg/min rate, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> occurred more frequently than at a 100 mg/min rate. The maximum rate of infusion studied was 200 mg/‌min.</p>
<p>Adverse reactions reported by at least 0.5% of all subjects/patients in clinical trials of valproate sodium injection are summarized in Table 1.</p>
<table>
<caption><span>Table 1. Adverse Reactions Reported During Studies of Valproate Sodium Injection</span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Body System/Reaction</span>
</td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">N = 463 </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Body as a Whole</span></td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td class="Botrule Lrule Rrule Toprule"> 1.7%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule"> 4.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection Site Inflammation</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection Site Pain</span></td>
<td class="Botrule Lrule Rrule Toprule"> 2.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule"> 2.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (unspecified)</td>
<td class="Botrule Lrule Rrule Toprule"> 1.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Cardiovascular</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> Vasodilation</td>
<td class="Botrule Lrule Rrule Toprule"> 0.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Dermatologic</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Digestive System</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule Lrule Rrule Toprule"> 1.1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule"> 3.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule"> 1.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Nervous System</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Lrule Rrule Toprule"> 1.7%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Respiratory</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Botrule Lrule Rrule Toprule"> 0.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Special Senses</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></td>
<td class="Botrule Lrule Rrule Toprule"> 1.9%</td>
</tr>
</tbody>
</table>
<p>In a separate clinical safety trial, 112 patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> were given infusions of valproate sodium injection (up to 15 mg/kg) over 5 to 10 minutes (1.5-3 mg/kg/min). The common adverse reactions (&gt; 2%) were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (10.7%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (7.1%), <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (7.1%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (7.1%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (6.3%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.7%). While the incidence of these adverse reactions was generally higher than in Table 1 (experience encompassing the standard, much slower infusion rates), e.g., <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1.7%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (5.2%), <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (0.9%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (0%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3.2%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (4.3%), a direct comparison between the incidence of adverse reactions in the 2 cohorts cannot be made because of differences in patient populations and study designs.</p>
<p><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">Ammonia</span> levels have not been systematically studied after IV valproate, so that an estimate of the incidence of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> after IV valproate sodium injection cannot be provided. <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> with <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> has been reported in 2 patients after infusions of valproate sodium injection.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_132160f1-1e33-429e-80f2-14aaa19415e8"></a><a name="section-6.1"></a><p></p>
<h2>6.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">Based on a placebo-controlled trial of adjunctive therapy for treatment of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>, divalproex sodium was generally well tolerated with most adverse reactions rated as mild to moderate in severity. Intolerance was the primary reason for discontinuation in the divalproex sodium-treated patients (6%), compared to 1% of placebo-treated patients.</p>
<p>Table 2 lists treatment-emergent adverse reactions which were reported by ≥ 5% of divalproex sodium-treated patients and for which the incidence was greater than in the placebo group, in the placebo-controlled trial of adjunctive therapy for treatment of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>. Since patients were also treated with other antiepilepsy drugs, it is not possible, in most cases, to determine whether the following adverse reactions can be ascribed to divalproex sodium alone, or the combination of divalproex sodium and other antiepilepsy drugs.</p>
<table>
<caption><span>Table 2. Adverse Reactions Reported by ≥ 5% of Patients Treated with Divalproex Sodium During Placebo-Controlled Trial of Adjunctive Therapy for <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span></span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Body System/Reaction</span>
</td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Divalproex Sodium (%)<br>(n = 77) </span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Placebo (%)<br>(n = 70)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Body as a Whole</span></td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule"> 31</td>
<td class="Botrule Lrule Rrule Toprule"> 21</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 27</td>
<td class="Botrule Lrule Rrule Toprule"> 7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Gastrointestinal System</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule"> 48</td>
<td class="Botrule Lrule Rrule Toprule"> 14</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule"> 27</td>
<td class="Botrule Lrule Rrule Toprule"> 7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule Lrule Rrule Toprule"> 23</td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule"> 13</td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 12</td>
<td class="Botrule Lrule Rrule Toprule"> 0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 8</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Nervous System</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Lrule Rrule Toprule"> 27</td>
<td class="Botrule Lrule Rrule Toprule"> 11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Lrule Rrule Toprule"> 25</td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule"> 25</td>
<td class="Botrule Lrule Rrule Toprule"> 13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 16</td>
<td class="Botrule Lrule Rrule Toprule"> 9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>/<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td class="Botrule Lrule Rrule Toprule"> 12</td>
<td class="Botrule Lrule Rrule Toprule"> 9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 8</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span></td>
<td class="Botrule Lrule Rrule Toprule"> 8</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span></td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking Abnormal</span></td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
<td class="Botrule Lrule Rrule Toprule"> 0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Respiratory System</span></td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span></td>
<td class="Botrule Lrule Rrule Toprule"> 12</td>
<td class="Botrule Lrule Rrule Toprule"> 9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Botrule Lrule Rrule Toprule"> 12</td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Other</span></td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></td>
<td class="Botrule Lrule Rrule Toprule"> 6</td>
<td class="Botrule Lrule Rrule Toprule"> 0</td>
</tr>
</tbody>
</table>
<p>Table 3 lists treatment-emergent adverse reactions which were reported by ≥ 5% of patients in the high dose valproate group, and for which the incidence was greater than in the low dose group, in a controlled trial of divalproex sodium monotherapy treatment of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>. Since patients were being titrated off another antiepilepsy drug during the first portion of the trial, it is not possible, in many cases, to determine whether the following adverse reactions can be ascribed to divalproex sodium alone, or the combination of valproate and other antiepilepsy drugs.</p>
<table>
<caption><span>Table 3. Adverse Reactions Reported by ≥ 5% of Patients in the High Dose Group in the Controlled Trial of Valproate Monotherapy for <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col>
<col>
<col>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was the only adverse reaction that occurred in ≥ 5% of patients in the high dose group and at an equal or greater incidence in the low dose group.</p></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Body System/Reaction</span>
</td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">High Dose (%)<br>(n = 131)</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Low Dose (%)<br>(n = 134) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Body as a Whole</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> </span></td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 21</td>
<td class="Botrule Lrule Rrule Toprule"> 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Digestive System</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule"> 34</td>
<td class="Botrule Lrule Rrule Toprule"> 26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule"> 23</td>
<td class="Botrule Lrule Rrule Toprule"> 19</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule"> 23</td>
<td class="Botrule Lrule Rrule Toprule"> 15</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Botrule Lrule Rrule Toprule"> 12</td>
<td class="Botrule Lrule Rrule Toprule"> 9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 11</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 11</td>
<td class="Botrule Lrule Rrule Toprule"> 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Hemic/Lymphatic System</span></td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 24</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Metabolic/Nutritional</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></td>
<td class="Botrule Lrule Rrule Toprule"> 9</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></td>
<td class="Botrule Lrule Rrule Toprule"> 8</td>
<td class="Botrule Lrule Rrule Toprule"> 3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Nervous System</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Lrule Rrule Toprule"> 57</td>
<td class="Botrule Lrule Rrule Toprule"> 19</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Lrule Rrule Toprule"> 30</td>
<td class="Botrule Lrule Rrule Toprule"> 18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule Rrule Toprule"> 18</td>
<td class="Botrule Lrule Rrule Toprule"> 13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 15</td>
<td class="Botrule Lrule Rrule Toprule"> 9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Botrule Lrule Rrule Toprule"> 11</td>
<td class="Botrule Lrule Rrule Toprule"> 7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 7</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span></td>
<td class="Botrule Lrule Rrule Toprule"> 7</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Respiratory System</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Botrule Lrule Rrule Toprule"> 20</td>
<td class="Botrule Lrule Rrule Toprule"> 13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Botrule Lrule Rrule Toprule"> 8</td>
<td class="Botrule Lrule Rrule Toprule"> 2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule Lrule Rrule Toprule"> 5</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Skin and Appendages</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule Lrule Rrule Toprule"> 24</td>
<td class="Botrule Lrule Rrule Toprule"> 13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Special Senses</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> </td>
<td class="Botrule Lrule Rrule Toprule"> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>/<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td class="Botrule Lrule Rrule Toprule"> 8</td>
<td class="Botrule Lrule Rrule Toprule"> 4</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></td>
<td class="Botrule Lrule Rrule Toprule"> 7</td>
<td class="Botrule Lrule Rrule Toprule"> 1</td>
</tr>
</tbody>
</table>
<p>The following additional adverse reactions were reported by greater than 1% but less than 5% of the 358 patients treated with valproate in the controlled trials of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>:</p>
<p><span class="Underline">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Underline">Cardiovascular System</span>: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>.</p>
<p><span class="Underline">Digestive System</span>: <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">periodontal abscess</span>.</p>
<p><span class="Underline">Hemic and Lymphatic System</span>: <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechia</span>.</p>
<p><span class="Underline">Metabolic and Nutritional Disorders</span>: <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, SGPT increased.</p>
<p><span class="Underline">Musculoskeletal System</span>: <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>.</p>
<p><span class="Underline">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>.</p>
<p><span class="Underline">Respiratory System</span>: <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="Underline">Skin and Appendages</span>: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>.</p>
<p><span class="Underline">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<p><span class="Underline">Urogenital System</span>: <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c667f344-8077-4d38-9115-01136cb236c6"></a><a name="section-6.2"></a><p></p>
<h2>6.2 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">Although valproate sodium injection has not been evaluated for safety and efficacy in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> associated with bipolar disorder, the following adverse reactions not listed above were reported by 1% or more of patients from two placebo-controlled clinical trials of divalproex sodium tablets.</p>
<p><span class="Underline">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>.</p>
<p><span class="Underline">Cardiovascular System</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, vasodilation.</p>
<p><span class="Underline">Digestive System</span>: <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">Fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>.</p>
<p><span class="Underline">Musculoskeletal System</span>: <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthrosis</span>.</p>
<p><span class="Underline">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="4011620" conceptname="Catatonic reaction">catatonic reaction</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">reflexes increased</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Underline">Skin and Appendages</span>: <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">Furunculosis</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>.</p>
<p><span class="Underline">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.</p>
<p><span class="Underline">Urogenital</span>: <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9c52aa2d-9f27-4cd3-9b77-c61230f74f30"></a><a name="section-6.3"></a><p></p>
<h2>6.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">Although valproate sodium injection has not been evaluated for safety and efficacy in the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>, the following adverse reactions not listed above were reported by 1% or more of patients from two placebo-controlled clinical trials of divalproex sodium tablets.</p>
<p><span class="Underline">Body as a Whole</span>: Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p><span class="Underline">Digestive System</span>: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>.</p>
<p><span class="Underline">Urogenital System</span>: <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, and <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ae180bea-1f6c-46ea-8cea-2302df49b0d5"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Postmarketing
Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of valproate sodium injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Underline">Dermatologic</span>: Hair texture changes, <span class="product-label-link" type="condition" conceptid="4242607" conceptname="Hair discoloration">hair color changes</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>.</p>
<p><span class="Underline">Neurologic</span>: There have been several reports of acute or subacute cognitive decline and behavioral changes (<span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>) with cerebral pseudoatrophy on imaging associated with valproate therapy; both the cognitive/behavioral changes and cerebral pseudoatrophy reversed partially or fully after valproate discontinuation.</p>
<p><span class="Underline">Psychiatric</span>: Emotional upset, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4085156" conceptname="Developmental academic disorder">learning disorder</span>, and behavioral deterioration.</p>
<p><span class="Underline">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>, decreased bone mineral density, <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Underline">Hematologic</span>: Relative <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>,  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> including macrocytic with or without <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>, bone marrow suppression, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span>.</p>
<p><span class="Underline">Endocrine</span>: Irregular menses, secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4029582" conceptname="Hyperandrogenization syndrome">hyperandrogenism</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, elevated testosterone level, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, parotid gland <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> disease, decreased carnitine concentrations, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, hyperglycinemia, and <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate ADH secretion</span>.</p>
<p>There have been rare reports of Fanconi's syndrome occurring chiefly in children.</p>
<p><span class="Underline">Genitourinary</span>: <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Enuresis</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</p>
<p><span class="Underline">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span>.</p>
<p><span class="Underline">Other</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_17266c45-cb57-428f-9e0a-08815b20594d"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_663e7a2b-d6ee-460f-901e-d48070b140dc"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effects of Co-Administered Drugs on Valproate Clearance</h2>
<p class="First">Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltransferases (such as ritonavir), may increase the clearance of valproate. For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate. Thus, patients on monotherapy will generally have longer half-lives and higher concentrations than patients receiving polytherapy with antiepilepsy drugs. </p>
<p>In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. </p>
<p>Because of these changes in valproate clearance, monitoring of valproate and concomitant drug concentrations should be increased whenever enzyme inducing drugs are introduced or withdrawn. </p>
<p>The following list provides information about the potential for an influence of several commonly prescribed medications on valproate pharmacokinetics. The list is not exhaustive nor could it be, since new interactions are continuously being reported. </p>
<p><span class="Underline">Drugs for which a potentially important interaction has been observed </span></p>
<p><span class="Italics">Aspirin<br></span>A study involving the co-administration of aspirin at antipyretic doses (11 to 16 mg/kg) with valproate to pediatric patients (n = 6) revealed a decrease in protein binding and an inhibition of metabolism of valproate. </p>
<p>Valproate free fraction was increased 4-fold in the presence of aspirin compared to valproate alone. The β-oxidation pathway consisting of 2-E-valproic acid, 3-OH-valproic acid, and 3-keto valproic acid was decreased from 25% of total metabolites excreted on valproate alone to 8.3% in the presence of aspirin. Caution should be observed if valproate and aspirin are to be co‑administered. </p>
<p><span class="Italics">Carbapenem Antibiotics<br></span>A clinically significant reduction in serum valproic acid concentration has been reported in patients receiving carbapenem antibiotics (for example, ertapenem, imipenem, meropenem this is not a complete list) and may result in loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control. The mechanism of this interaction is not well understood. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproic acid concentrations drop significantly or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control deteriorates [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_d0417f60-3a88-4b97-88be-95dee3062c3c">5.12</a>)</span>]. </p>
<p><span class="Italics">Felbamate<br></span>A study involving the co-administration of 1200 mg/day of felbamate with valproate to patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (n = 10) revealed an increase in mean valproate peak concentration by 35% (from 86 to 115 mcg/mL) compared to valproate alone. Increasing the felbamate dose to 2400 mg/‌day increased the mean valproate peak concentration to 133 mcg/mL (another 16% increase). A decrease in valproate dosage may be necessary when felbamate therapy is initiated. </p>
<p><span class="Italics">Rifampin<br></span>A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. Valproate dosage adjustment may be necessary when it is co-administered with rifampin. </p>
<p><span class="Underline">Drugs for which either no interaction or a likely clinically unimportant interaction has been observed </span></p>
<p><span class="Italics">Antacids<br></span>A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate. </p>
<p><span class="Italics">Chlorpromazine<br></span>A study involving the administration of 100 to 300 mg/day of chlorpromazine to schizophrenic patients already receiving valproate (200 mg BID) revealed a 15% increase in trough plasma levels of valproate. </p>
<p><span class="Italics">Haloperidol<br></span>A study involving the administration of 6 to 10 mg/day of haloperidol to schizophrenic patients already receiving valproate (200 mg BID) revealed no significant changes in valproate trough plasma levels. </p>
<p><span class="Italics">Cimetidine and Ranitidine<br></span>Cimetidine and ranitidine do not affect the clearance of valproate. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_63208369-dd09-4e71-add1-71ddc53bb919"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effects of Valproate on Other Drugs</h2>
<p class="First">Valproate has been found to be a weak inhibitor of some P450 isozymes, epoxide hydrase, and glucuronyl transferases. </p>
<p>The following list provides information about the potential for an influence of valproate co‑administration on the pharmacokinetics or pharmacodynamics of several commonly prescribed medications. The list is not exhaustive, since new interactions are continuously being reported. </p>
<p><span class="Underline">Drugs for which a potentially important valproate interaction has been observed </span></p>
<p><span class="Italics">Amitriptyline/Nortriptyline<br></span>Administration of a single oral 50 mg dose of amitriptyline to 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline. Rare postmarketing reports of concurrent use of valproate and amitriptyline resulting in an increased amitriptyline level have been received. Concurrent use of valproate and amitriptyline has rarely been associated with toxicity. Monitoring of amitriptyline levels should be considered for patients taking valproate concomitantly with amitriptyline. Consideration should be given to lowering the dose of amitriptyline/nortriptyline in the presence of valproate. </p>
<p><span class="Italics">Carbamazepine/carbamazepine-10,11-Epoxide<br></span>Serum levels of carbamazepine (CBZ) decreased 17% while that of carbamazepine-10,11-epoxide (CBZ-E) increased by 45% upon co-administration of valproate and CBZ to epileptic patients. </p>
<p><span class="Italics">Clonazepam<br></span>The concomitant use of valproate and clonazepam may induce absence status in patients with a history of absence type <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. </p>
<p><span class="Italics">Diazepam<br></span>Valproate displaces diazepam from its plasma albumin binding sites and inhibits its metabolism. Co-administration of valproate (1,500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n = 6). Plasma clearance and volume of distribution for free diazepam were reduced by 25% and 20%, respectively, in the presence of valproate. The elimination half‑life of diazepam remained unchanged upon addition of valproate. </p>
<p><span class="Italics">Ethosuximide<br></span>Valproate inhibits the metabolism of ethosuximide. Administration of a single ethosuximide dose of 500 mg with valproate (800 to 1,600 mg/day) to healthy volunteers (n = 6) was accompanied by a 25% increase in elimination half-life of ethosuximide and a 15% decrease in its total clearance as compared to ethosuximide alone. Patients receiving valproate and ethosuximide, especially along with other anticonvulsants, should be monitored for alterations in serum concentrations of both drugs. </p>
<p><span class="Italics">Lamotrigine<br></span>In a steady-state study involving 10 healthy volunteers, the elimination half-life of lamotrigine increased from 26 to 70 hours with valproate co-administration (a 165% increase). The dose of lamotrigine should be reduced when co-administered with valproate. Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported with concomitant lamotrigine and valproate administration. See lamotrigine package insert for details on lamotrigine dosing with concomitant valproate administration. </p>
<p><span class="Italics">Phenobarbital<br></span>Valproate was found to inhibit the metabolism of phenobarbital. Co-administration of valproate (250 mg BID for 14 days) with phenobarbital to normal subjects (n = 6) resulted in a 50% increase in half-life and a 30% decrease in plasma clearance of phenobarbital (60 mg single-dose). The fraction of phenobarbital dose excreted unchanged increased by 50% in presence of valproate. </p>
<p>There is evidence for severe <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, with or without significant elevations of barbiturate or valproate serum concentrations. All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate. </p>
<p>Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate. </p>
<p><span class="Italics">Phenytoin<br></span>Valproate displaces phenytoin from its plasma albumin binding sites and inhibits its hepatic metabolism. Co-administration of valproate (400 mg TID) with phenytoin (250 mg) in normal volunteers (n = 7) was associated with a 60% increase in the free fraction of phenytoin. Total plasma clearance and apparent volume of distribution of phenytoin increased 30% in the presence of valproate. Both the clearance and apparent volume of distribution of free phenytoin were reduced by 25%. </p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, there have been reports of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurring with the combination of valproate and phenytoin. The dosage of phenytoin should be adjusted as required by the clinical situation. </p>
<p><span class="Italics">Tolbutamide<br></span>From <span class="Italics">in vitro</span> experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate. The clinical relevance of this displacement is unknown. </p>
<p><span class="Italics">Warfarin<br></span>In an <span class="Italics">in vitro</span> study, valproate increased the unbound fraction of warfarin by up to 32.6%. The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants. </p>
<p><span class="Italics">Zidovudine<br></span>In six patients who were seropositive for HIV, the clearance of zidovudine (100 mg q8h) was decreased by 38% after administration of valproate (250 or 500 mg q8h); the half-life of zidovudine was unaffected. </p>
<p><span class="Underline">Drugs for which either no interaction or a likely clinically unimportant interaction has been observed </span></p>
<p><span class="Italics">Acetaminophen<br></span>Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients. </p>
<p><span class="Italics">Clozapine<br></span>In <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> patients (n = 11), no interaction was observed when valproate was co-administered with clozapine. </p>
<p><span class="Italics">Lithium<br></span>Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n = 16) had no effect on the steady-state kinetics of lithium. </p>
<p><span class="Italics">Lorazepam<br></span>Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n = 9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.</p>
<p><span class="Italics">Olanzapine<br></span>No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in Cmax and 35% reduction in AUC of olanzapine.</p>
<p><span class="Italics">Oral Contraceptive Steroids<br></span>Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5bc6d43e-ad54-4c6e-ac45-fdb8790eec2d"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Topiramate</h2>
<p class="First">Concomitant administration of valproate and topiramate has been associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with and without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> [see <span class="Bold">CONTRAINDICATIONS (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)</span> and <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_6b74d06c-f3ca-4651-85ec-07115d023be5">5.8</a>, <a href="#LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb">5.9</a></span>]. Concomitant administration of topiramate with valproate has also been associated with <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> in patients who have tolerated either drug alone. It may be prudent to examine blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels in patients in whom the onset of <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> has been reported [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_6b74d06c-f3ca-4651-85ec-07115d023be5">5.8</a>, <a href="#LINK_a590675a-3b5c-4092-a7a9-5fe7ab4e3878">5.10</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_4131ba19-89d3-477d-85da-29cf4941d0e0"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_3d64c32b-83e1-4932-925c-bf3fae007911"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span> for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>)</span>]. </p>
<p><span class="Italics">Pregnancy Registry<br></span>To collect information on the effects of <span class="Italics">in utero</span> exposure to valproate sodium injection, physicians should encourage pregnant patients taking valproate sodium injection to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling toll free 1-888‑233‑2334, and must be done by the patients themselves. Information on the registry can be found at the website, http://www.aedpregnancyregistry.org/. </p>
<p><span class="Italics">Fetal Risk Summary<br></span>All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (about 3%), pregnancy loss (about 15%), or other adverse outcomes regardless of drug exposure. Maternal valproate use during pregnancy for any indication increases the risk of congenital malformations, particularly <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, but also malformations involving other body systems (e.g., craniofacial defects, cardiovascular malformations, <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>, <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb malformations</span>). The risk of major structural abnormalities is greatest during the first trimester; however, other serious developmental effects can occur with valproate use throughout pregnancy. The rate of congenital malformations among babies born to epileptic mothers who used valproate during pregnancy has been shown to be about four times higher than the rate among babies born to epileptic mothers who used other anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> monotherapies [see <span class="Bold">Warnings and Precautions (<a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>)</span>]. </p>
<p>Several published epidemiological studies have indicated that children exposed to valproate <span class="Italics">in utero</span> have lower IQ scores than children exposed to either another antiepileptic drug <span class="Italics">in utero</span> or to no antiepileptic drugs <span class="Italics">in utero</span> [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>)</span>].</p>
<p>An observational study has suggested that exposure to valproate products during pregnancy may increase the risk of <span class="product-label-link" type="condition" conceptid="439776" conceptname="Pervasive developmental disorder">autism spectrum disorders</span>. In this study, children born to mothers who had used valproate products during pregnancy had 2.9 times the risk (95% confidence interval [CI]: 1.7-4.9) of developing <span class="product-label-link" type="condition" conceptid="439776" conceptname="Pervasive developmental disorder">autism spectrum disorders</span> compared to children born to mothers not exposed to valproate products during pregnancy. The absolute risks for <span class="product-label-link" type="condition" conceptid="439776" conceptname="Pervasive developmental disorder">autism spectrum disorders</span> were 4.4% (95% CI: 2.6%-7.5%) in valproate-exposed children and 1.5% (95% CI: 1.5%-1.6%) in children not exposed to valproate products. Because the study was observational in nature, conclusions regarding a causal association between <span class="Italics">in utero</span> valproate exposure and an increased risk of <span class="product-label-link" type="condition" conceptid="439776" conceptname="Pervasive developmental disorder">autism spectrum disorder</span> cannot be considered definitive.</p>
<p>In animal studies, offspring with prenatal exposure to valproate had structural malformations similar to those seen in humans and demonstrated neurobehavioral deficits. </p>
<p><span class="Italics">Clinical Considerations</span></p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">Neural tube defects</span> are the congenital malformation most strongly associated with maternal valproate use. The risk of <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> following <span class="Italics">in utero</span> valproate exposure is generally estimated as 1-2%, compared to an estimated general population risk for <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> of about 0.06 to 0.07% (6 to 7 in 10,000 births).</li>
<li>Valproate can cause decreased IQ scores in children whose mothers were treated with valproate during pregnancy.</li>
<li>Because of the risks of decreased IQ, <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, and other fetal adverse events, which may occur very early in pregnancy:<ul class="Circle">
<li>Valproate should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition. This is especially important when valproate use is considered for a condition not usually associated with permanent injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (e.g., <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>).</li>
<li>Valproate should not be used to treat women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> who are pregnant or who plan to become pregnant unless other treatments have failed to provide adequate symptom control or are otherwise unacceptable. In such women, the benefits of treatment with valproate during pregnancy may still outweigh the risks. When treating a pregnant woman or a woman of childbearing potential, carefully consider both the potential risks and benefits of treatment and provide appropriate counseling.</li>
</ul>
</li>
<li>To prevent major <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> should not discontinue valproate abruptly, as this can precipitate <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> with resulting maternal and fetal <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and threat to life. Even minor <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may pose some hazard to the developing embryo or fetus. However, discontinuation of the drug may be considered prior to and during pregnancy in individual cases if the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder severity and frequency do not pose a serious threat to the patient. 
</li>
<li>Available prenatal diagnostic testing to detect neural tube and other defects should be offered to pregnant women using valproate. 
</li>
<li>Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> in the general population. It is not known whether the risk of <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> or decreased IQ in the offspring of women receiving valproate is reduced by folic acid supplementation. Dietary folic acid supplementation both prior to conception and during pregnancy should be routinely recommended for patients using valproate.</li>
<li>Pregnant women taking valproate may develop clotting abnormalities including <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span>, and/or decrease in other coagulation factors, which may result in hemorrhagic complications in the neonate including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [see <span class="Bold">Warnings and Precautions</span><span class="Bold">(<a href="#LINK_cb12e87c-0574-46c5-b0a5-c603a0e2f452">5.7</a>)</span>]. If valproate is used in pregnancy, the clotting parameters should be monitored carefully in the mother. If abnormal in the mother, then these parameters should also be monitored in the neonate.</li>
<li>Patients taking valproate may develop <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> [see <span class="Bold"><a href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">BOXED WARNING</a></span> and <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span>]. Fatal cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in infants exposed to valproate <span class="Italics">in utero</span> have also been reported following maternal use of valproate during pregnancy.</li>
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> has been reported in neonates whose mothers have taken valproate during pregnancy.</li>
</ul>
<p><span class="Italics">Data</span></p>
<p><span class="Underline">Human</span></p>
<p>There is an extensive body of evidence demonstrating that exposure to valproate <span class="Italics">in utero</span> increases the risk of <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> and other structural abnormalities. Based on published data from the CDC’s National <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> Prevention Network, the risk of <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> in the general population is about 0.06 to 0.07%. The risk of <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> following <span class="Italics">in utero</span> valproate exposure has been estimated to be approximately 1 to 2%. </p>
<p>The NAAED Pregnancy Registry has reported a major malformation rate of 9-11% in the offspring of women exposed to an average of 1,000 mg/day of valproate monotherapy during pregnancy. These data show up to a five-fold increased risk for any major malformation following valproate exposure <span class="Italics">in utero </span>compared to the risk following exposure <span class="Italics">in utero</span> to other antiepileptic drugs taken in monotherapy. The major congenital malformations included cases of <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, cardiovascular malformations, craniofacial defects (e.g., oral clefts, <span class="product-label-link" type="condition" conceptid="4210998" conceptname="Craniosynostosis syndrome">craniosynostosis</span>), <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>, <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb malformations</span> (e.g., <span class="product-label-link" type="condition" conceptid="438242" conceptname="Talipes equinovarus">clubfoot</span>, <span class="product-label-link" type="condition" conceptid="74740" conceptname="Polydactyly">polydactyly</span>), and malformations of varying severity involving other body systems.</p>
<p>Published epidemiological studies have indicated that children exposed to valproate <span class="Italics">in utero</span> have lower IQ scores than children exposed to either another antiepileptic drug <span class="Italics">in utero</span> or to no antiepileptic drugs <span class="Italics">in utero</span>. The largest of these studies is a prospective cohort study conducted in the United States and United Kingdom that found that children with prenatal exposure to valproate (n = 62) had lower IQ scores at age 6 (97 [95% C.I. 94-101]) than children with prenatal exposure to the other anti-epileptic drug monotherapy treatments evaluated: lamotrigine (108 [95% C.I. 105–110]), carbamazepine (105 [95% C.I. 102–108]) and phenytoin (108 [95% C.I. 104–112]). It is not known when during pregnancy cognitive effects in valproate-exposed children occur. Because the women in this study were exposed to antiepileptic drugs throughout pregnancy, whether the risk for decreased IQ was related to a particular time period during pregnancy could not be assessed.</p>
<p>Although all of the available studies have methodological limitations, the weight of the evidence supports a causal association between valproate exposure <span class="Italics">in utero</span> and subsequent adverse effects on cognitive development. </p>
<p>There are published case reports of fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in offspring of women who used valproate during pregnancy. </p>
<p><span class="Underline">Animal</span></p>
<p>In developmental toxicity studies conducted in mice, rats, rabbits, and monkeys, increased rates of fetal structural abnormalities, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> occurred following treatment of pregnant animals with valproate during organogenesis at clinically relevant doses (calculated on a body surface area basis). Valproate induced malformations of multiple organ systems, including skeletal, cardiac, and urogenital defects. In mice, in addition to other malformations, fetal <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> have been reported following valproate administration during critical periods of organogenesis, and the teratogenic response correlated with peak maternal drug levels. Behavioral abnormalities (including cognitive, locomotor, and social interaction deficits) and brain histopathological changes have also been reported in mice and rat offspring exposed prenatally to clinically relevant doses of valproate.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_367b4528-5767-4d83-97da-5a405ca061e0"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Valproate is excreted in human milk. Caution should be exercised when valproate is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_2de9de63-7015-4729-94e1-92c1738623fa"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Experience with oral valproate has indicated that pediatric patients under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those with the aforementioned conditions [see <span class="Bold"><a href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">BOXED WARNING</a></span>]. The safety of valproate sodium injection has not been studied in individuals below the age of 2 years. If a decision is made to use valproate sodium injection in this age group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. Above the age of 2 years, experience in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> has indicated that the incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups. </p>
<p>Younger children, especially those receiving enzyme-inducing drugs, will require larger maintenance doses to attain targeted total and unbound valproate concentrations. </p>
<p>The variability in free fraction limits the clinical usefulness of monitoring total serum valproic acid concentrations. Interpretation of valproic acid concentrations in children should include consideration of factors that affect hepatic metabolism and protein binding. </p>
<p><span class="Underline">Pediatric Clinical Trials </span></p>
<p>No unique safety concerns were identified in the 35 patients age 2 to 17 years who received valproate sodium injection in clinical trials. </p>
<p>One twelve-month study was conducted to evaluate the safety of divalproex sodium sprinkle capsules in the indication of <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> (169 patients aged 3 to 10 years). The safety and tolerability of divalproex sodium in pediatric patients were shown to be comparable to those in adults [see <span class="Bold">ADVERSE REACTIONS (<a href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</a>)</span>]. </p>
<p><span class="Underline">Juvenile Animal Toxicology </span></p>
<p>In studies of valproate in immature animals, toxic effects not observed in adult animals included retinal <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> in rats treated during the neonatal period (from postnatal day 4) and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> in rats treated during the neonatal and juvenile (from postnatal day 14) periods. The no-effect dose for these findings was less than the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_313c8236-c268-4d4e-8899-6c558f8f3a58"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No patients above the age of 65 years were enrolled in double-blind prospective clinical trials of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> associated with bipolar illness. In a case review study of 583 patients, 72 patients (12%) were greater than 65 years of age. A higher percentage of patients above 65 years of age reported <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Discontinuation of valproate was occasionally associated with the latter two events. It is not clear whether these events indicate additional risk or whether they result from preexisting medical illness and concomitant medication use among these patients. </p>
<p>A study of elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> revealed drug related <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and discontinuation for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_e520f86e-c406-42ba-9e77-7f6badf42d01">5.13</a>)</span>]. The starting dose should be reduced in these patients, and dosage reductions or discontinuation should be considered in patients with excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> [see <span class="Bold">DOSAGE AND ADMINISTRATION (<a href="#LINK_3572552b-3ca0-4674-be7e-53d8dd0ccb44">2.2</a>)</span>].</p>
<p>No unique safety concerns were identified in the 21 patients &gt; 65 years of age receiving valproate sodium injection in clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_76922bd7-15a9-47b4-9eed-781a842e50c2"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage with valproate may result in <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, deep <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>. Fatalities have been reported; however patients have recovered from valproate serum concentrations as high as 2120 mcg/mL.</p>
<p>In <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations, the fraction of drug not bound to protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may result in significant removal of drug. General supportive measures should be applied with particular attention to the maintenance of adequate urinary output.</p>
<p>Naloxone has been reported to reverse the CNS depressant effects of valproate overdosage. Because naloxone could theoretically also reverse the antiepilepsy effects of valproate, it should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_270240c8-24da-44ce-af8d-3341abaa6a73"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Valproate sodium is the sodium salt of valproic acid designated as sodium 2-propylpentanoate. Valproate sodium has the following structure:</p>
<div class="Figure"><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268&amp;name=valproate-sodium-injection---novaplus-1.jpg"></div>
<p>Valproate sodium has a molecular weight of 166.2. It occurs as an essentially white and odorless, crystalline, deliquescent powder.</p>
<p>Valproate Sodium Injection, USP is available in 5 mL single dose vials for intravenous injection. Each mL contains valproate sodium equivalent to 100 mg valproic acid, edetate disodium 0.40 mg, and water for injection to volume. The pH is adjusted to 7.6 with sodium hydroxide and/‌or hydrochloric acid. The solution is clear and colorless.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_b2e74910-6622-4ed1-8296-a59406ca0f2a"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_44e3e2c1-4e9c-49f3-9f4a-ae93ab70f634"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Valproate sodium injection exists as the valproate ion in the blood. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> is related to increased brain concentrations of gamma-aminobutyric acid (GABA).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_1a08c30c-33d2-4898-b57c-8dd379621245"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The relationship between plasma concentration and clinical response is not well documented. One contributing factor is the nonlinear, concentration dependent protein binding of valproate which affects the clearance of the drug. Thus, monitoring of total serum valproate cannot provide a reliable index of the bioactive valproate species.</p>
<p>For example, because the plasma protein binding of valproate is concentration dependent, the free fraction increases from approximately 10% at 40 mcg/mL to 18.5% at 130 mcg/mL. Higher than expected free fractions occur in the elderly, in hyperlipidemic patients, and in patients with hepatic and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal diseases</span>. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span><br></span>The therapeutic range in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> is commonly considered to be 50 to 100 mcg/mL of total valproate, although some patients may be controlled with lower or higher plasma concentrations.</p>
<p>Equivalent doses of valproate sodium injection and divalproex sodium yield equivalent plasma levels of the valproate ion [see <span class="Bold">CLINICAL PHARMACOLOGY (<a href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Bioavailability<br></span>Equivalent doses of intravenous (IV) valproate and oral valproate products are expected to result in equivalent C<span class="Sub">max</span>, C<span class="Sub">min</span>, and total systemic exposure to the valproate ion when the IV valproate is administered as a 60 minute infusion. However, the rate of valproate ion absorption may vary with the formulation used. These differences should be of minor clinical importance under the steady state conditions achieved in chronic use in the treatment of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. </p>
<p>Administration of divalproex sodium tablets and IV valproate (given as a one hour infusion), 250 mg every 6 hours for 4 days to 18 healthy male volunteers resulted in equivalent AUC, C<span class="Sub">max</span>, C<span class="Sub">min</span> at steady state, as well as after the first dose. The T<span class="Sub">max</span> after IV valproate sodium injection occurs at the end of the one hour infusion, while the T<span class="Sub">max</span> after oral dosing with divalproex sodium occurs at approximately 4 hours. Because the kinetics of unbound valproate are linear, bioequivalence between valproate sodium injection and divalproex sodium up to the maximum recommended dose of 60 mg/kg/day can be assumed. The AUC and C<span class="Sub">max </span>resulting from administration of IV valproate 500 mg as a single one hour infusion and a single 500 mg dose of valproic acid syrup to 17 healthy male volunteers were also equivalent. </p>
<p>Patients maintained on valproic acid doses of 750 mg to 4250 mg daily (given in divided doses every 6 hours) as oral divalproex sodium alone (n = 24) or with another stabilized antiepileptic drug [carbamazepine (n = 15), phenytoin (n = 11), or phenobarbital (n = 1)], showed comparable plasma levels for valproic acid when switching from oral divalproex sodium to IV valproate (1‑hour infusion). </p>
<p>Eleven healthy volunteers were given single infusions of 1000 mg IV valproate over 5, 10, 30, and 60 minutes in a 4-period crossover study. Total valproate concentrations were measured; unbound concentrations were not measured. After the 5 minute infusions (mean rate of 2.8 mg/‌kg/‌min), mean C<span class="Sub">max</span> was 145 ± 32 mcg/mL, while after the 60 minute infusions, mean C<span class="Sub">max</span> was 115 ± 8 mcg/‌mL. Ninety to 120 minutes after infusion initiation, total valproate concentrations were similar for all 4 rates of infusion. Because protein binding is nonlinear at higher total valproate concentrations, the corresponding increase in unbound C<span class="Sub">max</span> at faster infusion rates will be greater. </p>
<p><span class="Underline">Distribution<br></span><span class="Italics">Protein Binding<br></span>The plasma protein binding of valproate is concentration dependent and the free fraction increases from approximately 10% at 40 mcg/mL to 18.5% at 130 mcg/mL. Protein binding of valproate is reduced in the elderly, in patients with chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic diseases</span>, in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and in the presence of other drugs (e.g., aspirin). Conversely, valproate may displace certain protein-bound drugs (e.g., phenytoin, carbamazepine, warfarin, and tolbutamide) (see <span class="Bold">DRUG INTERACTIONS (<a href="#LINK_63208369-dd09-4e71-add1-71ddc53bb919">7.2</a>)</span> for more detailed information on the <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> of valproate with other drugs). </p>
<p><span class="Italics">CNS Distribution<br></span>Valproate concentrations in cerebrospinal fluid (CSF) approximate unbound concentrations in plasma (about 10% of total concentration). </p>
<p><span class="Underline">Metabolism<br></span>Valproate is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial β-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine. </p>
<p>The relationship between dose and total valproate concentration is nonlinear; concentration does not increase proportionally with the dose, but rather, increases to a lesser extent due to saturable plasma protein binding. The kinetics of unbound drug are linear. </p>
<p><span class="Underline">Elimination<br></span>Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m<span class="Sup">2</span> and 11 L/1.73 m<span class="Sup">2</span>, respectively. Mean terminal half-life for valproate monotherapy after an intravenous infusion of 1,000 mg was 16 ± 3.0 hours. </p>
<p>The estimates cited apply primarily to patients who are not taking drugs that affect hepatic metabolizing enzyme systems. For example, patients taking enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin, and phenobarbital) will clear valproate more rapidly. Because of these changes in valproate clearance, monitoring of antiepileptic concentrations should be intensified whenever concomitant antiepileptics are introduced or withdrawn. </p>
<p><span class="Underline">Special Populations<br></span><span class="Italics">Effect of Age<br></span>Neonates:<br>Children within the first two months of life have a markedly decreased ability to eliminate valproate compared to older children and adults. This is a result of reduced clearance (perhaps due to delay in development of glucuronosyltransferase and other enzyme systems involved in valproate elimination) as well as increased volume of distribution (in part due to decreased plasma protein binding). For example, in one study, the half-life in children under 10 days ranged from 10 to 67 hours compared to a range of 7 to 13 hours in children greater than 2 months.</p>
<p>Children:<br>Pediatric patients (i.e., between 3 months and 10 years) have 50% higher clearances expressed on weight (i.e., mL/min/kg) than do adults. Over the age of 10 years, children have pharmacokinetic parameters that approximate those of adults. </p>
<p>Elderly:<br>The capacity of elderly patients (age range: 68 to 89 years) to eliminate valproate has been shown to be reduced compared to younger adults (age range: 22 to 26). Intrinsic clearance is reduced by 39%; the free fraction is increased by 44%. Accordingly, the initial dosage should be reduced in the elderly [see <span class="Bold">DOSAGE AND ADMINISTRATION (<a href="#LINK_3572552b-3ca0-4674-be7e-53d8dd0ccb44">2.2</a>)</span>]. </p>
<p><span class="Italics">Effect of Sex<br></span>There are no differences in the body surface area adjusted unbound clearance between males and females (4.8 ± 0.17 and 4.7 ± 0.07 L/hr per 1.73 m<span class="Sup">2</span>, respectively). </p>
<p><span class="Italics">Effect of Race<br></span>The effects of race on the kinetics of valproate have not been studied. </p>
<p><span class="Italics">Effect of Disease <br></span>Liver Disease:<br>Liver disease impairs the capacity to eliminate valproate. In one study, the clearance of free valproate was decreased by 50% in 7 patients with cirrhosis and by 16% in 4 patients with acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, compared with 6 healthy subjects. In that study, the half-life of valproate was increased from 12 to 18 hours. Liver disease is also associated with decreased albumin concentrations and larger unbound fractions (2 to 2.6 fold increase) of valproate. Accordingly, monitoring of total concentrations may be misleading since free concentrations may be substantially elevated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> whereas total concentrations may appear to be normal [see <span class="Bold"><a href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">BOXED WARNING</a></span>, <span class="Bold">CONTRAINDICATIONS (<a href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</a>)</span>, and <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span>]. </p>
<p><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span>:<br>A slight reduction (27%) in the unbound clearance of valproate has been reported in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (creatinine clearance &lt; 10 mL/minute); however, hemodialysis typically reduces valproate concentrations by about 20%. Therefore, no dosage adjustment appears to be necessary in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Protein binding in these patients is substantially reduced; thus, monitoring total concentrations may be misleading. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_17d4e9cd-7b7f-4bc1-9322-9c34024eea7b"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_808a0b7e-82d1-4e86-a48b-49a6a789972e"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis<br></span>Valproate was administered orally to rats and mice at doses of 80 and 170 mg/kg/day (less than the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) for two years. The primary findings were an increase in the incidence of subcutaneous <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> in high-dose male rats receiving valproate and a dose-related trend for benign pulmonary <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in male mice receiving valproate. The significance of these findings for humans is unknown. </p>
<p><span class="Underline">Mutagenesis<br></span>Valproate was not mutagenic in an <span class="Italics">in vitro</span> bacterial assay (Ames test), did not produce dominant lethal effects in mice, and did not increase chromosome aberration frequency in an <span class="Italics">in vivo</span> cytogenetic study in rats. Increased frequencies of sister chromatid exchange (SCE) have been reported in a study of epileptic children taking valproate, but this association was not observed in another study conducted in adults. There is some evidence that increased SCE frequencies may be associated with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. The biological significance of an increase in SCE frequency is not known. </p>
<p><span class="Underline">Fertility<br></span>Chronic toxicity studies of valproate in juvenile and adult rats and dogs demonstrated reduced spermatogenesis and <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> at oral doses of 400 mg/kg/day or greater in rats (approximately equivalent to or greater than the maximum recommended human dose (MRHD) on a mg/m<span class="Sup">2</span> basis) and 150 mg/kg/day or greater in dogs (approximately 1.4 times the MRHD or greater on a mg/m<span class="Sup">2</span> basis). Fertility studies in rats have shown no effect on fertility at oral doses of valproate up to 350 mg/kg/day (approximately equal to the MRHD dose on a mg/m<span class="Sup">2</span> basis) for 60 days. The effect of valproate on testicular development and on sperm production and fertility in humans is unknown. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_4ef60d23-9b54-4faa-a092-111267f448ff"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The studies described in the following section were conducted with oral divalproex sodium products.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_dc29ed9f-f44d-4891-b623-e037e97e5791"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">The efficacy of valproate in reducing the incidence of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> (CPS) that occur in isolation or in association with other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types was established in two controlled trials. </p>
<p>In one, multiclinic, placebo controlled study employing an add-on design (adjunctive therapy), 144 patients who continued to suffer eight or more CPS per 8 weeks during an 8 week period of monotherapy with doses of either carbamazepine or phenytoin sufficient to assure plasma concentrations within the “therapeutic range? were randomized to receive, in addition to their original antiepilepsy drug (AED), either divalproex sodium or placebo. Randomized patients were to be followed for a total of 16 weeks. The following Table presents the findings.</p>
<table>
<caption><span>Table 4. Adjunctive Therapy Study Median Incidence of CPS per 8 Weeks</span></caption>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Reduction from baseline statistically significantly greater for valproate than placebo at p ≤ 0.05 level.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Add-on Treatment</span>
</td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Number of Patients</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Baseline Incidence </span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Experimental Incidence</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> Divalproex sodium</td>
<td class="Botrule Lrule Rrule Toprule"> 75</td>
<td class="Botrule Lrule Rrule Toprule"> 16.0</td>
<td class="Botrule Lrule Rrule Toprule"> 8.9<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> Placebo</td>
<td class="Botrule Lrule Rrule Toprule"> 69</td>
<td class="Botrule Lrule Rrule Toprule"> 14.5</td>
<td class="Botrule Lrule Rrule Toprule"> 11.5</td>
</tr>
</tbody>
</table>
<p>Figure 1 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates was at least as great as that indicated on the Y axis in the adjunctive therapy study. A positive percent reduction indicates an improvement (i.e., a decrease in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for an effective treatment is shifted to the left of the curve for placebo. This Figure shows that the proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo. For example, 45% of patients treated with valproate had a ≥ 50% reduction in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rate compared to 23% of patients treated with placebo.</p>
<div class="Figure">
<img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268&amp;name=valproate-sodium-injection---novaplus-2.jpg"><p class="MultiMediaCaption">Figure 1</p>
</div>
<p>The second study assessed the capacity of valproate to reduce the incidence of CPS when administered as the sole AED. The study compared the incidence of CPS among patients randomized to either a high or low dose treatment arm. Patients qualified for entry into the randomized comparison phase of this study only if 1) they continued to experience 2 or more CPS per 4 weeks during an 8 to 12 week long period of monotherapy with adequate doses of an AED (i.e., phenytoin, carbamazepine, phenobarbital, or primidone) and 2) they made a successful transition over a two week interval to valproate. Patients entering the randomized phase were then brought to their assigned target dose, gradually tapered off their concomitant AED and followed for an interval as long as 22 weeks. Less than 50% of the patients randomized, however, completed the study. In patients converted to divalproex sodium monotherapy, the mean total valproate concentrations during monotherapy were 71 and 123 mcg/mL in the low dose and high dose groups, respectively.</p>
<p>The following Table presents the findings for all patients randomized who had at least one post‑randomization assessment.</p>
<table>
<caption><span>Table 5. Monotherapy Study Median Incidence of CPS per 8 Weeks</span></caption>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd><p class="First">Reduction from baseline statistically significantly greater for high dose than low dose at p ≤ 0.05 level.</p></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Treatment</span>
</td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"> Number of Patients</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Baseline Incidence </span></td>
<td class="Botrule Lrule Rrule Toprule">
<span class="Bold">Randomized Phase Incidence</span> </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> High dose divalproex sodium</td>
<td class="Botrule Lrule Rrule Toprule"> 131</td>
<td class="Botrule Lrule Rrule Toprule"> 13.2</td>
<td class="Botrule Lrule Rrule Toprule"> 10.7<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> Low dose divalproex sodium</td>
<td class="Botrule Lrule Rrule Toprule"> 134</td>
<td class="Botrule Lrule Rrule Toprule"> 14.2</td>
<td class="Botrule Lrule Rrule Toprule"> 13.8</td>
</tr>
</tbody>
</table>
<p>Figure 2 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates was at least as great as that indicated on the Y axis in the monotherapy study. A positive percent reduction indicates an improvement (i.e., a decrease in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for a more effective treatment is shifted to the left of the curve for a less effective treatment. This Figure shows that the proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate. For example, when switching from carbamazepine, phenytoin, phenobarbital or primidone monotherapy to high dose valproate monotherapy, 63% of patients experienced no change or a reduction in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates compared to 54% of patients receiving low dose valproate.</p>
<div class="Figure">
<img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268&amp;name=valproate-sodium-injection---novaplus-3.jpg"><p class="MultiMediaCaption">Figure 2</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_592896b1-c6b4-4f37-b792-db7f4e92e945"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic"><li>Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology 2013; 12 (3):244-252.</li></ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_dd887705-9ac2-46cb-9de4-1970f5ede59c"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Valproate Sodium Injection, USP, equivalent to 100 mg of valproic acid per mL, is a clear, colorless solution in 5 mL single dose vials, available in trays of 10 vials (NDC 0143-9637-10).</p>
<p>Recommended storage: Store vials at 20° to 25°C (68° to 77°F) with excursions between 15° and 30°C (59° and 86°F) [See USP Controlled Room Temperature]. </p>
<p>No preservatives have been added. Unused portion of container should be discarded.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Underline">Hepatotoxicity </span></p>
<p>Warn patients and guardians that <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and/or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> can be symptoms of hepatotoxicity and, therefore, require further medical evaluation promptly [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_0f251f46-71f5-43bb-b0d9-c4c3e49c707f">5.1</a>)</span>]. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> </span></p>
<p>Warn patients and guardians that <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> can be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and, therefore, require further medical evaluation promptly [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_88f2fc36-7a47-48db-b98b-fd688ae57f0e">5.5</a>)</span>]. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> and Decreased IQ</span></p>
<p>Inform pregnant women and women of childbearing potential that use of valproate during pregnancy increases the risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and decreased IQ in children who were exposed.</p>
<p>Advise women to use effective contraception while using valproate. When appropriate, counsel these patients about alternative therapeutic options. This is particularly important when valproate use is considered for a condition not usually associated with permanent injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_8ce9430d-57d5-45b3-863a-3a62957de503">5.2</a>, <a href="#LINK_e1d330d0-b9fb-4aaf-886b-7111a37f5f90">5.3</a>, <a href="#LINK_57047296-0423-46d6-b660-a5feaf241ca2">5.4</a>)</span> and <span class="Bold">USE IN SPECIFIC POPULATIONS (<a href="#LINK_3d64c32b-83e1-4932-925c-bf3fae007911">8.1</a>)</span>]. </p>
<p>Advise women of childbearing potential to discuss pregnancy planning with their doctor and to contact their doctor immediately if they think they are pregnant.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> </span></p>
<p>Inform patients of the signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> and be told to inform the prescriber if any of these symptoms occur [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_6b74d06c-f3ca-4651-85ec-07115d023be5">5.8</a>, <a href="#LINK_3b8e441c-b0d7-438e-9f3b-1c87a6366ceb">5.9</a>)</span>]. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span> </span></p>
<p>Since valproate products may produce <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, especially when combined with another CNS depressant (e.g., alcohol), advise patients not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug. </p>
<p><span class="Underline">Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>Instruct patients that a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> associated with other organ system involvement (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, etc.) may be drug-related and should be reported to the physician immediately [see <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_0712022e-aec0-4130-825e-80aa14a5ed16">5.11</a>)</span>].</p>
<p><span class="Bold">Manufactured by: </span>HIKMA FARMACÊUTICA (PORTUGAL), S.A.<br>Estrada do Rio da Mó, 8, 8A e 8B - Fervença - 2705-906 Terrugem SNT, PORTUGAL</p>
<p><span class="Bold">Distributed by: </span>WEST-WARD PHARMACEUTICAL CORP.<br>Eatontown, NJ 07724 USA</p>
<p>N<span class="Sup">+</span> and NOVAPLUS are registered trademarks of Novation, LLC.</p>
<p>Revised: 05/2015</p>
<p>PIN321-NOV/2</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_ce659607-e36e-405d-a7ba-0984862466c7"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0143-9637-01<br>VALPROATE Sodium Injection, USP<br>FOR IV INFUSION ONLY<br>500 mg/5 mL<br>(100 mg/mL)<br>5 mL Single Dose Vial<br>Rx ONLY</p>
<p> <img alt="NDC 0143-9637-01 VALPROATE Sodium Injection, USP FOR IV INFUSION ONLY 500 mg/5 mL (100 mg/mL) 5 mL Single Dose Vial Rx ONLY" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268&amp;name=valproate-sodium-injection---novaplus-4.jpg"></p>
<p>NDC 0143-9637-10<br>VALPROATE Sodium Injection, USP<br>FOR INTRAVENOUS INFUSION ONLY<br>500 mg/5 mL<br>(100 mg/mL)<br>10 X 5 mL Single Dose Vials<br>Rx ONLY</p>
<div class="Figure"><img alt="NDC 0143-9637-10 VALPROATE Sodium Injection, USP FOR INTRAVENOUS INFUSION ONLY 500 mg/5 mL (100 mg/mL) 10 X 5 mL Single Dose Vials Rx ONLY" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268&amp;name=valproate-sodium-injection---novaplus-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALPROATE SODIUM 		
					</strong><br><span class="contentTableReg">valproate sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-9637</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALPROATE SODIUM</strong> (VALPROIC ACID) </td>
<td class="formItem">VALPROIC ACID</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.40 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9637-10</td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9637-01</td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078523</td>
<td class="formItem">04/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>West-Ward Pharmaceutical Corp
							(001230762)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>West-ward Pharmaceutical Corp (001230762)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">HIKMA FARMACEUTICA (PORTUGAL), S.A</td>
<td class="formItem"></td>
<td class="formItem">452742943</td>
<td class="formItem">ANALYSIS(0143-9637), LABEL(0143-9637), MANUFACTURE(0143-9637), PACK(0143-9637)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>40eb78e6-77df-4a2a-9e7a-ae35b1fd7af8</div>
<div>Set id: 7a687b2f-246d-4736-a20c-92421c263268</div>
<div>Version: 2</div>
<div>Effective Time: 20150618</div>
</div>
</div> <div class="DistributorName">West-Ward Pharmaceutical Corp</div></p>
</body></html>
